Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.78 USD | +11.27% |
|
-76.29% | -75.78% |
06-18 | Oppenheimer Downgrades Ovid Therapeutics to Market Perform | MT |
06-18 | B. Riley Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-75.78% | 55.34M | |
+15.19% | 121B | |
+19.91% | 114B | |
+18.37% | 23.61B | |
-19.80% | 20.43B | |
-15.66% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B |
- Stock Market
- Equities
- OVID Stock
- News Ovid Therapeutics Inc.
- Ligand Acquires 13% Stake in Ovid Therapeutics' Soticlestat Royalties for $30 Million